MX2020013728A - Combinacion de inmunoterapias con inhibidores de mdm2. - Google Patents

Combinacion de inmunoterapias con inhibidores de mdm2.

Info

Publication number
MX2020013728A
MX2020013728A MX2020013728A MX2020013728A MX2020013728A MX 2020013728 A MX2020013728 A MX 2020013728A MX 2020013728 A MX2020013728 A MX 2020013728A MX 2020013728 A MX2020013728 A MX 2020013728A MX 2020013728 A MX2020013728 A MX 2020013728A
Authority
MX
Mexico
Prior art keywords
combination
immunotherapies
mdm2 inhibitors
effective amount
mdm2
Prior art date
Application number
MX2020013728A
Other languages
English (en)
Inventor
Qiuqiong Tang
Dajun Yang
Yifan Zhai
Douglas Dong Fang
Original Assignee
Ascentage Pharma Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascentage Pharma Suzhou Co Ltd filed Critical Ascentage Pharma Suzhou Co Ltd
Publication of MX2020013728A publication Critical patent/MX2020013728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer en el presente documento terapias de combinación que comprenden una cantidad eficaz de un modulador de la molécula de punto de control inmunitario; y una cantidad eficaz de un inhibidor de MDM2. (ver Fórmula).
MX2020013728A 2018-08-08 2019-08-07 Combinacion de inmunoterapias con inhibidores de mdm2. MX2020013728A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018099280 2018-08-08
CN2018124866 2018-12-28
CN2019073720 2019-01-29
US201962853069P 2019-05-27 2019-05-27
PCT/CN2019/099664 WO2020030016A1 (en) 2018-08-08 2019-08-07 Combination of immunotherapies with mdm2 inhibitors

Publications (1)

Publication Number Publication Date
MX2020013728A true MX2020013728A (es) 2021-05-27

Family

ID=69414548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013728A MX2020013728A (es) 2018-08-08 2019-08-07 Combinacion de inmunoterapias con inhibidores de mdm2.

Country Status (11)

Country Link
US (1) US20220175725A1 (es)
EP (1) EP3833445A4 (es)
JP (1) JP2021534088A (es)
KR (1) KR20210073490A (es)
CN (1) CN110812478B (es)
AU (1) AU2019316865A1 (es)
BR (1) BR112021002303A2 (es)
CL (1) CL2021000300A1 (es)
MX (1) MX2020013728A (es)
TW (1) TWI786322B (es)
WO (1) WO2020030016A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020169073A1 (en) * 2019-02-24 2020-08-27 Ascentage Pharma (Suzhou) Co., Ltd. Treatment methods and biomarkers for mdm2 inhibitors
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
WO2021207598A1 (en) * 2020-04-10 2021-10-14 Aprea Therapeutics, Inc. Combination treatment with an agonist of p53 and a second therapeutic agent
US20230149356A1 (en) * 2020-04-14 2023-05-18 Ascentage Pharma (Suzhou) Co., Ltd. Novel medical use of mdm2 inhibitors
CN113801120B (zh) * 2020-06-15 2024-03-22 苏州亚盛药业有限公司 Mdm2抑制剂的微悬浮液以及治疗应用
WO2022063220A1 (en) * 2020-09-25 2022-03-31 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
WO2022177995A1 (en) * 2021-02-17 2022-08-25 University Of Florida Research Foundation, Incorporated Anti-lair1 antibodies for the treatment of cancer
WO2023033113A1 (ja) 2021-09-01 2023-03-09 クロステクノロジーラボ株式会社 電気二重層キャパシタを介する電子伝導機能を有する電池

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015247646B2 (en) * 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
EP3925622A1 (en) * 2014-09-13 2021-12-22 Novartis AG Combination therapies
BR112018070549A2 (pt) * 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
WO2018185135A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Also Published As

Publication number Publication date
BR112021002303A2 (pt) 2021-05-04
KR20210073490A (ko) 2021-06-18
TW202021582A (zh) 2020-06-16
JP2021534088A (ja) 2021-12-09
US20220175725A1 (en) 2022-06-09
TWI786322B (zh) 2022-12-11
WO2020030016A1 (en) 2020-02-13
CN110812478A (zh) 2020-02-21
EP3833445A4 (en) 2022-04-27
EP3833445A1 (en) 2021-06-16
AU2019316865A1 (en) 2020-12-17
CN110812478B (zh) 2021-05-25
CL2021000300A1 (es) 2021-10-29

Similar Documents

Publication Publication Date Title
MX2020013728A (es) Combinacion de inmunoterapias con inhibidores de mdm2.
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
GEP20217234B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
IL276095A (en) gcn2 inhibitors and their uses
IL276147A (en) GCN2 inhibitors and uses thereof
PH12018501848A1 (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
MX2021003559A (es) Inhibidores de vap-1.
EP3870173A4 (en) WDR5 MODULATORS AND INHIBITORS
MY188849A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2021003731A (es) Inhibidores de vap-1.
AU201715152S (en) Ramp
IL288306A (en) Combined treatments using cdk inhibitors
MX2020013657A (es) Combinacion de factor vii y de un anticuerpo biespecifico dirigido contra los factores ix y x.
EP3854224A4 (en) IMMUNE CHECKPOINT INHIBITOR
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
EP3790895A4 (en) CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER
IL308868A (en) Combined treatments with SETD2 inhibitors
CR20210463A (es) Inhibidores de arginasa y métodos de uso de estos
MX2020007375A (es) Terapias de combinacion para el tratamiento de carcinoma hepatocelular.
EP3762401A4 (en) CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR
CA187926S (en) Eyeglasses